{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:11:27Z","timestamp":1792498287323,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["200166"],"award-info":[{"award-number":["200166"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jval.2021.11.1358","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T02:13:38Z","timestamp":1642040018000},"page":"1018-1029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index"],"prefix":"10.1016","volume":"25","author":[{"given":"Matthew","family":"Franklin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael Maree","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Enrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2021.11.1358_bib1","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"issue":"suppl 1","key":"10.1016\/j.jval.2021.11.1358_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40273-017-0544-y","article-title":"International regulations and recommendations for utility data for health technology assessment","volume":"35","author":"Rowen","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.jval.2021.11.1358_bib3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10198-020-01195-8","article-title":"Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines","volume":"21","author":"Kennedy-Martin","year":"2020","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2021.11.1358_bib5","series-title":"Measuring and Valuing Health Benefits for Economic Evaluation","author":"Brazier","year":"2016"},{"issue":"suppl 1","key":"10.1016\/j.jval.2021.11.1358_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40273-017-0545-x","article-title":"A\u00a0review of generic preference-based measures for use in cost-effectiveness models","volume":"35","author":"Brazier","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2021.11.1358_bib7","author":"Brazier"},{"issue":"suppl 1","key":"10.1016\/j.jval.2021.11.1358_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40273-017-0546-9","article-title":"The role of condition-specific preference-based measures in health technology assessment","volume":"35","author":"Rowen","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1358_bib9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jval.2011.12.003","article-title":"Condition-specific preference-based measures: benefit or burden?","volume":"15","author":"Versteegh","year":"2012","journal-title":"Value Health"},{"issue":"suppl 3","key":"10.1016\/j.jval.2021.11.1358_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1258\/jhsrp.2008.008015","article-title":"Measuring and valuing mental health for use in economic evaluation","volume":"13","author":"Brazier","year":"2008","journal-title":"J\u00a0Health Serv Res Policy"},{"key":"10.1016\/j.jval.2021.11.1358_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhealeco.2020.102303","article-title":"The relative value of different QALY types","volume":"70","author":"Lancsar","year":"2020","journal-title":"J\u00a0Health Econ"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1358_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0167-6296(88)90030-6","article-title":"A\u00a0QALY is a QALY--or is it?","volume":"7","author":"Weinstein","year":"1988","journal-title":"J\u00a0Health Econ"},{"issue":"12","key":"10.1016\/j.jval.2021.11.1358_bib13","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A\u00a0guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1358_bib14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40273-019-00771-y","article-title":"An educational review about using cost data for the purpose of cost-effectiveness analysis","volume":"37","author":"Franklin","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2021.11.1358_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40273-014-0247-6","article-title":"An educational review of the statistical issues in analysing utility data for cost-utility analysis","volume":"33","author":"Hunter","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2021.11.1358_bib16","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s11136-014-0873-7","article-title":"Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients","volume":"24","author":"Golicki","year":"2015","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.jval.2021.11.1358_bib17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s11136-014-0838-x","article-title":"Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample","volume":"24","author":"Buchholz","year":"2015","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.jval.2021.11.1358_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1524-4733.2007.00230.x","article-title":"Comparing the standard EQ-5D three-level system with a five-level version","volume":"11","author":"Janssen","year":"2008","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1358_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mlr.0000254515.63841.81","article-title":"Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients","volume":"45","author":"Pickard","year":"2007","journal-title":"Med Care"},{"issue":"7","key":"10.1016\/j.jval.2021.11.1358_bib20","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s11136-012-0318-0","article-title":"Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases","volume":"22","author":"Scalone","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2021.11.1358_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S1098-3015(11)71846-0","article-title":"Psychometric comparison of EQ-5D and EQ-5D-5L in student population","volume":"13","author":"Golicki","year":"2010","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2021.11.1358_bib22","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.jval.2021.11.1358_bib23","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jval.2014.04.002","article-title":"A\u00a0program of methodological research to arrive at the new international EQ-5D-5L valuation protocol","volume":"17","author":"Oppe","year":"2014","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1358_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jval.2018.05.010","article-title":"Overview, update, and lessons learned from the International EQ-5D-5L valuation work: version 2 of the EQ-5D-5L valuation protocol","volume":"22","author":"Stolk","year":"2019","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1358_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1358_bib26","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/hec.1596","article-title":"A\u00a0uniform time trade off method for states better and worse than dead: feasibility study of the \u2018lead time\u2019 approach","volume":"20","author":"Devlin","year":"2011","journal-title":"Health Econ"},{"issue":"suppl 1","key":"10.1016\/j.jval.2021.11.1358_bib27","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s10198-013-0503-2","article-title":"Introducing the composite time trade-off: a test of feasibility and face validity","volume":"14","author":"Janssen","year":"2013","journal-title":"Eur J Health Econ"},{"issue":"7","key":"10.1016\/j.jval.2021.11.1358_bib28","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1097\/MLR.0000000000000283","article-title":"Valuation and modeling of EQ-5D-5L health states using a hybrid approach","volume":"55","author":"Ramos-Go\u00f1i","year":"2017","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1358_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/0272989X14559542","article-title":"A\u00a0comparison of methods for converting DCE values onto the full health-dead QALY scale","volume":"35","author":"Rowen","year":"2015","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2021.11.1358_bib31","unstructured":"Hern\u00e1ndez-Alava M, Pudney S, Wailoo A. Quality Review of a Proposed EQ-5D-5L Value Set for England [EEPRU report] [online];\u00a02018."},{"issue":"5","key":"10.1016\/j.jval.2021.11.1358_bib32","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jval.2019.11.008","article-title":"Competing views on the English EQ-5D-5L valuation set","volume":"23","author":"Norman","year":"2020","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1358_bib33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jval.2019.10.013","article-title":"The EQ-5D-5L value set for England: response to the \u201cQuality Assurance\u201d","volume":"23","author":"van Hout","year":"2020","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1358_bib34","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2021.11.1358_bib35","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1358_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40258-019-00467-6","article-title":"An updated systematic review of studies mapping (or Cross-Walking) measures of health-related quality of life to generic preference-based measures to generate utility values","volume":"17","author":"Mukuria","year":"2019","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2021.11.1358_bib37","author":"Longworth"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1358_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13104-019-4067-9","article-title":"Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results","volume":"12","author":"Gerlinger","year":"2019","journal-title":"BMC Res Notes"},{"issue":"6","key":"10.1016\/j.jval.2021.11.1358_bib39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40273-018-0628-3","article-title":"Comparing the UK EQ-5D-3L and English EQ-5D-5L value sets [published correction appears in Pharmacoeconomics. 2018;36(6):727]","volume":"36","author":"Mulhern","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1358_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jval.2017.09.004","article-title":"EQ-5D-5L versus EQ-5D-3L: the impact on cost effectiveness in the United Kingdom","volume":"21","author":"Hernandez Alava","year":"2018","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2021.11.1358_bib41","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jval.2020.11.012","article-title":"An international comparison of EQ-5D-5L and EQ-5D-3L for use in cost-effectiveness analysis","volume":"24","author":"Wailoo","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2021.11.1358_bib42","series-title":"Mental Health Economics","article-title":"Cost utility analysis","author":"Franklin","year":"2017"},{"key":"10.1016\/j.jval.2021.11.1358_bib43","series-title":"Mental Health Economics: The Costs and Benefits of Psychiatric Care","author":"Razzouk","year":"2017"},{"issue":"34","key":"10.1016\/j.jval.2021.11.1358_bib44","doi-asserted-by":"crossref","DOI":"10.3310\/hta18340","article-title":"A\u00a0systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures","volume":"18","author":"Brazier","year":"2014","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1358_bib45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1192\/bjp.bp.112.122283","article-title":"Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D","volume":"205","author":"Mulhern","year":"2014","journal-title":"Br J Psychiatry"},{"issue":"11","key":"10.1016\/j.jval.2021.11.1358_bib46","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40273-015-0295-6","article-title":"Can the EQ-5D detect meaningful change? A systematic review","volume":"33","author":"Payakachat","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2021.11.1358_bib47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10198-017-0902-x","article-title":"What is the evidence for the performance of generic preference-based measures? A systematic overview of reviews","volume":"19","author":"Finch","year":"2018","journal-title":"Eur J Health Econ"},{"issue":"9","key":"10.1016\/j.jval.2021.11.1358_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18090","article-title":"Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey","volume":"18","author":"Longworth","year":"2014","journal-title":"Health Technol Assess"},{"issue":"9904","key":"10.1016\/j.jval.2021.11.1358_bib49","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2021.11.1358_bib50","author":"McManus"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1358_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40258-020-00607-3","article-title":"Systematic review and critique of methods for economic evaluation of digital mental health interventions","volume":"19","author":"Jankovic","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"10.1016\/j.jval.2021.11.1358_bib52","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/09540261.2011.606803","article-title":"Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: the IAPT experience","volume":"23","author":"Clark","year":"2011","journal-title":"Int Rev Psychiatry"},{"issue":"9","key":"10.1016\/j.jval.2021.11.1358_bib53","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.brat.2013.06.004","article-title":"Enhancing recovery rates: lessons from year one of IAPT","volume":"51","author":"Gyani","year":"2013","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.jval.2021.11.1358_bib54","unstructured":"The Improving Access to Psychological Therapies Manual. NHS Digital. https:\/\/www.england.nhs.uk\/publication\/the-improving-access-to-psychological-therapies-manual\/. Accessed December 12, 2021."},{"issue":"1","key":"10.1016\/j.jval.2021.11.1358_bib55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1099-1050(199902)8:1<41::AID-HEC395>3.0.CO;2-#","article-title":"A\u00a0checklist for judging preference-based measures of health related quality of life: learning from psychometrics","volume":"8","author":"Brazier","year":"1999","journal-title":"Health Econ"},{"issue":"9","key":"10.1016\/j.jval.2021.11.1358_bib56","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hec.866","article-title":"A\u00a0comparison of the EQ-5D and SF\u22126D across seven patient groups","volume":"13","author":"Brazier","year":"2004","journal-title":"Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1358_bib57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.2017.10","article-title":"Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties","volume":"212","author":"Keetharuth","year":"2018","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.jval.2021.11.1358_bib58","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jval.2020.10.012","article-title":"Estimating a Preference-Based Index for mental health from the Recovering Quality of Life measure: valuation of Recovering Quality of Life Utility Index","volume":"24","author":"Keetharuth","year":"2021","journal-title":"Value Health"},{"issue":"9","key":"10.1016\/j.jval.2021.11.1358_bib59","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1007\/s11136-021-02833-1","article-title":"Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: construct validity and responsiveness","volume":"30","author":"Franklin","year":"2021","journal-title":"Qual Life Res"},{"issue":"9","key":"10.1016\/j.jval.2021.11.1358_bib60","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J\u00a0Gen Intern Med"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1358_bib61","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-146-5-200703060-00004","article-title":"Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection","volume":"146","author":"Kroenke","year":"2007","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jval.2021.11.1358_bib62","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A\u00a0brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1358_bib63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12888-018-1639-5","article-title":"Digital IAPT: the effectiveness & cost-effectiveness of internet-delivered interventions for depression and anxiety disorders in the Improving Access to Psychological Therapies programme: study protocol for a randomised control trial","volume":"18","author":"Richards","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jval.2021.11.1358_bib64","first-page":"1","article-title":"A\u00a0pragmatic randomized waitlist-controlled effectiveness and cost-effectiveness trial of digital interventions for depression and anxiety","volume":"3","author":"Richards","year":"2020","journal-title":"npj Digit Med"},{"issue":"suppl 20","key":"10.1016\/j.jval.2021.11.1358_bib65","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jval.2021.11.1358_bib66","unstructured":"Microsoft excel 2016. Microsoft Corporation."},{"issue":"8","key":"10.1016\/j.jval.2021.11.1358_bib67","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40273-018-0650-5","article-title":"Sensitivity analysis for not-at-random missing data in trial-based cost-effectiveness analysis: a tutorial [published correction appears in Pharmacoeconomics. 2019;37(7):971]","volume":"36","author":"Leurent","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2021.11.1358_bib68","series-title":"Stata Statistical Software: Release 15","year":"2017"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1358_bib69","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1524-4733.2005.00045.x","article-title":"Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report","volume":"8","author":"Ramsey","year":"2005","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2021.11.1358_bib70","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II\u2014an ISPOR Good Research Practices Task Force report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2021.11.1358_bib71","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) -- explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2021.11.1358_bib72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2288-14-75","article-title":"Tuning multiple imputation by predictive mean matching and local residual draws","volume":"14","author":"Morris","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jval.2021.11.1358_bib73","series-title":"Statistical Analysis With Missing Data","author":"Little","year":"2002"},{"issue":"4","key":"10.1016\/j.jval.2021.11.1358_bib74","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.jval.2021.11.1358_bib75","series-title":"Statistical Analysis With Missing Data","author":"Little","year":"2019"},{"issue":"2","key":"10.1016\/j.jval.2021.11.1358_bib76","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1740774507076914","article-title":"Cost-effectiveness in clinical trials: using multiple imputation to deal with incomplete cost data","volume":"4","author":"Burton","year":"2007","journal-title":"Clin Trials"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1358_bib77","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hec.843","article-title":"Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data","volume":"13","author":"Willan","year":"2004","journal-title":"Health Econ"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1358_bib78","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"issue":"12","key":"10.1016\/j.jval.2021.11.1358_bib79","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/hec.901","article-title":"Calculation of quality adjusted life years in the published literature: a review of methodology and transparency","volume":"13","author":"Richardson","year":"2004","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2021.11.1358_bib80","author":"Hern\u00e1ndez Alava"},{"key":"10.1016\/j.jval.2021.11.1358_bib81","series-title":"Oxford Guide to Low Intensity CBT Interventions","author":"Bennett-Levy","year":"2010"},{"issue":"6","key":"10.1016\/j.jval.2021.11.1358_bib82","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1192\/bjp.bp.110.083733","article-title":"Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis","volume":"199","author":"Leamy","year":"2011","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jval.2021.11.1358_bib83","author":"Shepherd"},{"key":"10.1016\/j.jval.2021.11.1358_bib84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12888-015-0678-4","article-title":"Empirical evidence about recovery and mental health","volume":"15","author":"Slade","year":"2015","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.jval.2021.11.1358_bib85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2975\/31.1.2007.9.22","article-title":"An analysis of the definitions and elements of recovery: a review of the literature","volume":"31","author":"Onken","year":"2007","journal-title":"Psychiatr Rehabil J"},{"issue":"8","key":"10.1016\/j.jval.2021.11.1358_bib87","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042003","article-title":"Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model","volume":"7","author":"Ramsberg","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jval.2021.11.1358_bib88","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40273-014-0138-x","article-title":"Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium","volume":"32","author":"Annemans","year":"2014","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2021.11.1358_bib90","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0272989X14543107","article-title":"Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments","volume":"35","author":"Richardson","year":"2015","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2021.11.1358_bib91","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521031892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521031892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:27:03Z","timestamp":1761096423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521031892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1098301521031892"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2021.11.1358","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating Cost-Effectiveness Using Alternative Preference-Based Scores and Within-Trial Methods: Exploring the Dynamics of the Quality-Adjusted Life-Year Using the EQ-5D 5-Level Version and Recovering Quality of Life Utility Index","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2021.11.1358","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}